Trastuzumab Duocarmazine provides a HER2-targeting antibody-drug conjugate (ADC) for cancer and oncology research. Also known as SYD985, it combines trastuzumab with a duocarmycin-derived DNA-alkylating payload and specifically supports studies of HER2-targeted cytotoxicity, DNA damage, and antibody-mediated drug delivery.
Key Features and Benefits
- HER2-Targeting ADC: Combines the HER2-directed monoclonal antibody trastuzumab with a duocarmycin-derived cytotoxic payload.
- Duocarmycin Payload: Contains a potent DNA-alkylating agent that specifically supports investigation of ADC-mediated cytotoxicity.
- HER2 Recognition: Supports studies of HER2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker specifically designed to facilitate release of the active duocarmycin payload.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of DNA-alkylating agents to HER2-expressing cancer cells.
- DNA Alkylation Mechanism: The released payload damages DNA through alkylation, specifically supporting studies of cell death and cytotoxic responses.
- Bystander Effect: The membrane-permeable payload supports investigation of cytotoxic effects in neighboring tumor cells.
- SYD985 Research Platform: Provides an investigational ADC platform specifically for studying HER2-directed targeting and DNA-alkylating payload activity.
Applications
- HER2-Positive Breast Cancer Research: Supports investigation of HER2-targeted ADC mechanisms in HER2-positive breast cancer models.
- HER2-Low Breast Cancer Research: Useful for studying ADC activity in tumor models with lower HER2 expression.
- HER2-Expressing Solid Tumor Research: Supports investigation of HER2-directed ADC strategies across relevant solid tumor models.
- ADC Research: Useful for studying antibody targeting, internalization, payload release, and cytotoxic activity.
- DNA Damage Research: Supports investigation of duocarmycin-mediated DNA alkylation and associated cellular responses.
- Targeted Cancer Research: Useful for investigating antibody-mediated delivery of DNA-alkylating cytotoxic payloads.
- Cell-Based Cancer Assays: Supports evaluation of HER2-dependent binding, cellular uptake, and cytotoxic responses.
- Bystander Killing Research: Useful for studying payload-mediated effects on neighboring cancer cells with varying HER2 expression.
- Comparative ADC Research: Supports comparison of HER2-targeted ADCs with different linker systems and cytotoxic payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and potent DNA-alkylating research materials. Maintain conditions that preserve antibody and conjugate stability.
Trastuzumab Duocarmazine combines HER2-directed antibody targeting with a duocarmycin-derived DNA-alkylating payload and specifically supports HER2-positive and HER2-low breast cancer, DNA damage, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
